YORK, Pa., Oct. 29, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) announced today that, due to severe weather conditions and expected power outages in the Northeastern region of the U.S., it has decided to reschedule the release of its results for the fiscal 2013 first quarter ended September 30, 2012. Unilife will now release its fiscal 2013 first quarter results and 10-Q on Thursday, November 8 at 4:05 p.m. (U.S. Eastern Standard Time).
The Unilife conference call with analysts will be rescheduled to occur on Thursday, November 8 at 4:30 p.m. (U.S. Eastern Standard Time) (Australian time is Friday, November 9, 2012 at 8:30 a.m. AEDT). The conference call will be broadcast over the Internet as a "live" listen only Webcast. To listen, please go to: http://ir.unilife.com/events.cfm. Listeners are urged to login approximately 20 minutes before the conference call is scheduled to begin in order to register, as well as download and install any necessary audio software. An archive of the webcast will be available on the Company's website.
Shareholders seeking an update on Unilife prior to November 8th are encouraged to refer to a two-part video interview series conducted with an analyst from Griffin Securities, Inc. that was released by the Company last week. The video interviews and associated transcripts are available on the Unilife website at www.unilife.com. The videos are also available on YouTube: video 1: http://youtu.be/X-LbVnzk1W0; and video 2: http://youtu.be/tDTeWn6UJLQ.
About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of advanced drug delivery systems. Unilife collaborates with pharmaceutical and biotechnology companies seeking innovative, differentiated devices that can enable or enhance the delivery of injectable drugs and vaccines supplied in either a liquid stable or lyophilized form. The Unifill syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of this diversified portfolio. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms including drug reconstitution delivery systems, auto-injectors, auto-infusion pump systems and specialized devices for targeted organ delivery. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information on Unilife, please visit www.unilife.com.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.
Investor Contacts (US):
Investor Contacts (Australia)
Todd Fromer / Garth Russell
KCSA Strategic Communications
P: + 1 212-896-1215 / 212-896-1250
P: + 1 415-202-5678
P: + 61 2 8346 6500
SOURCE Unilife Corporation